Introduction {#Sec1}
============

The need for a selective, high affinity A~2B~ adenosine receptor (AdoR) antagonist, to fully establish the therapeutic potential of this class of agents as anti-inflammatory and antiangiogenic agents, has attracted the interest of several medicinal chemistry groups around the world \[[@CR1]--[@CR11]\]. The structural approach taken by these groups can be divided into two classes of compounds, xanthines and non-xanthine derivatives. The xanthine derivatives caffeine and theophylline are considered classic nonselective antagonists for adenosine receptors (Fig. [1](#Fig1){ref-type="fig"}). Theophylline **1**, which has 9 µM affinity for the A~2B~ AdoR, displays no selectivity against the other AdoRs \[[@CR12]\]. Enprofylline **2**, a 3-propyl xanthine derivative has moderate A~2B~ affinity and low selectivity over the other AdoRs. Following further structural exploration of the xanthine moiety by several groups, the discovery of 8-phenylxanthines as selective A~2B~ AdoR antagonists was made \[[@CR13]--[@CR15]\]. Among these 8-phenylxanthine derivatives, *p*-cyanoanilide **3** (MRS-1754) of Jacobson et al. \[[@CR16]\] and a negatively charged compound **4** (PSB-1115) of Muller et al. \[[@CR17]\] stand out as selective A~2B~ AdoR antagonists. To address the metabolic stability of compound **3** in human liver microsomal enzymes, Zablocki et al. \[[@CR18]\] synthesized compound **5** (CVT-5440) that contains a bioisostere of the metabolically labile amide group present in **3**. Compound **5** demonstrated good affinity for the A~2B~ AdoR and selectivity over the other AdoRs. Improved in vitro metabolic stability was also observed in **5** compared to **3**, but **5** still has a very low systemic exposure in rats when dosed orally, presumably due to low solubility. Fig. 1Classic and prototypical xanthine-derived A~2B~ receptor antagonists

Xanthines {#Sec2}
=========

CV Therapeutics (CVT) chemists started with these initial leads in their search for the discovery of a selective, high affinity A~2B~ AdoR antagonist with good pharmaceutical properties \[[@CR19], [@CR20]\]. Kalla et al. \[[@CR21]\] have explored various heterocycles as bioisosteric replacements for the phenyl group at the 8-position of xanthine and discovered that the 8-(pyrazol-4-yl)xanthines display good A~2B~ AdoR affinity (Fig. [2](#Fig2){ref-type="fig"}). The prototypical compound 1,3-dipropyl-8-(1*H*-pyrazol-4-yl)xanthine **6** (CVT-5450) has high A~2B~ AdoR affinity (9 nM), but displayed very low selectivity. Following oral dosing in rats, **6** displayed very high levels of systemic exposure; this encouraged CVT chemists to probe the 8-(pyrazol-4-yl)xanthine ligand to increase the selectivity \[[@CR8]\]. Benzyl substitution on the pyrazole ring increased the selectivity compared to the phenyl, phenethyl, and phenpropyl derivatives. Optimization of the phenyl ring substitution suggested that the electron withdrawing groups F and CF~3~ at the *meta*-position increased selectivity toward the A~2B~ AdoR. Compound **7**, 1,3-dipropyl-8-(1-(3-(trifluoromethyl)benzyl)-1*H*-pyrazol-4-yl)xanthine that has 3-CF~3~ benzyl substitution on the pyrazole ring, displayed better selectivity compared to the unsubstituted derivative **6**. Replacing the 1,3-dipropyl groups of the xanthine core with various alkyl groups like methyl, ethyl, butyl, and isobutyl groups suggested that smaller alkyl groups relative to propyl increase the A~2B~ AdoR affinity and selectivity compared to the large groups. Compound 1,3-dimethyl-8-(1-(3-(trifluoromethyl)benzyl)-1*H*-pyrazol-4-yl)-xanthine **8** (CVT-6975) has very high A~2B~ AdoR affinity and selectivity \[[@CR21]\]. This observation prompted further investigation of the differential alkyl substitution at N-1 and N-3 positions \[[@CR22]\]. Compound **9** displayed better affinity and selectivity compared to the dipropyl derivative **7**, but has weaker affinity and selectivity compared to the dimethyl derivative **8**. The 3-ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1*H*-pyrazol-4-yl)-xanthine **10** (CVT-6883) has very good A~2B~ AdoR affinity, and also it displayed good selectivity over other AdoR subtypes \[[@CR22]\]. Fig. 2CVT A~2B~ adenosine receptor antagonists---8-(pyrazol-4-yl) xanthines

Investigation of the monosubstitution at the N-1 position of the 8-pyrazolyl xanthine delivered a very high affinity and selective A~2B~ AdoR antagonists \[[@CR23]\]. For example, the 1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1*H*-pyrazol-4-yl)-xanthine **11** (CVT-7124) displays high A~2B~ AdoR affinity (6 nM) and very good selectivity. This further supports the Hayallah et al. observation in the 8-phenyl xanthine series of compounds, that the monosubstitution at the N-1 position of the xanthine core enhances the A~2B~ AdoR selectivity \[[@CR17]\].

Elzein et al. replaced the phenyl group of **7** with different heterocycles including 3-phenyl-1,2,4-oxadiazoles, 5-phenyl-1,2,4-oxadiazoles and 3-phenyl-isoxazoles as these groups in the 8-phenyl xanthine series \[[@CR18]\] improved the selectivity for the A~2B~ AdoR receptor (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR24]\]. In this series, all the compounds display very good selectivity regardless of the substitutions at the N-1 and N-3 positions of the xanthine core. The 1,3-dipropyl analogue 8-(1-((5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl)methyl)-1*H*-pyrazol-4-yl)-xanthine **12** and N-1 propyl, N-3 ethyl analogues 3-ethyl-1-propyl-8-(1-((5-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)methyl)-xanthine **13** and 3-ethyl-1-propyl-8-(1-((5-(4-(trifluoromethyl)phenyl) isoxazol-3-yl)methyl)-1*H*-pyrazol-4-yl)-xanthine **14** display high affinity and selectivity for the A~2B~ AdoR. Similar to the phenyl series of compounds, the N-1 monosubstituted oxadiazole and isoxazole derivatives of 8-pyrazolyl xanthines displayed high affinity and selectivity for the A~2B~ AdoR. The N-1 propyl derivative **15** (CVT-6694) has a very high A~2B~ affinity (7 nM) and very weak affinity for the A~1~, A~2A~, and A~3~ AdoRs \[[@CR23]\]. The cyclopropyl methyl analogues **16** and **17** also displayed high affinity and selectivity for the A~2B~ AdoR. Fig. 3CVT A~2B~ adenosine receptor antagonists---8-(pyrazol-4-yl)xanthines

In summary, CVT chemists discovered several high affinity and selective A~2B~ AdoR antagonists. The pharmacophore, 8-(pyrazol-4-yl)xanthine, identified by the CVT chemists can provide selective A~2B~ AdoR antagonists depending on the substitution pattern. From the above compounds, two selective antagonists **10** (CVT-6883) and **15** (CVT-6694) were chosen for further evaluation of the pharmacological and pharmaceutical properties. Compound **10** antagonized the 5′-*N*-ethylcarboxamidoadenosine (NECA)-induced cyclic adenosine monophosphate (cAMP) accumulation in human embryonic kidney (HEK)-A~2B~ cells and NIH 3T3 cells, and compound **15** completely abolished the NECA-induced cAMP accumulation in bronchial smooth muscle cells (BSMCs) \[[@CR25]\] proving that these compounds are functioning as antagonists for the hA~2B~ AdoR. Compound **10**, when dosed orally in rats at 2 mg/kg, displayed excellent systemic exposure with a C~max~ 1,100 ng/ml and dose-adjusted area under curve (dAUC) 6,500 ng.h/ml \[[@CR22]\] with a long half-life of 4 h (IV dosing, rat). When dosed orally in rats compound **15** exhibited very low systemic exposure. Therefore, compound **10** was selected as a lead molecule and moved into CVT's development program.

Baraldi's group evaluated a series of 8-heterocyclic substituted xanthines as antagonists for the A~2B~ AdoR \[[@CR26]\]. Of these derivatives, 8-(pyrazol-5-yl)xanthine derivatives displayed high affinity and selectivity for the A~2B~ AdoR (Fig. [4](#Fig4){ref-type="fig"}). These 5-pyrazolyl derivatives **18** and **19** showed good affinity for the A~2B~ AdoR and selectivity over other AdoR subtypes \[[@CR27]\]. Both compounds block NECA-induced cAMP accumulation with IC~50~ values in the nanomolar range. Further exploration of the 5-pyrazolyl class resulted in a lead compound **20** (MRE-2029-F20) that has high affinity and selectivity for the A~2B~ AdoR. The tritium-labeled derivative **21** (\[^3^H\]MRE-2029-F20) displayed a *K*~D~ value of 1.65 ± 0.10 nM in Chinese hamster ovary (CHO) cells expressing hA~2B~ receptors, and it can be useful as a pharmacological tool in binding studies \[[@CR28]\]. Fig. 4Baraldi's A~2B~ adenosine receptor antagonists

In recent patent applications, Adenosine Therapeutics described a series of 8-pyridyl substituted xanthines as A~2B~ AdoR antagonists (Fig. [5](#Fig5){ref-type="fig"}) \[[@CR29]\]. The 8-pyridyl was further extended by substitution with heteroaryl (**23** and **25**), heterocyclyl (**22**), or alaninol (**24**) groups. According to the patent applications, some of these derivatives (**22--25**) have an A~2B~ AdoR affinity of \< 100 nM, but no selectivity data were given, so it is hard to completely evaluate the series. Fig. 5Adenosine Therapeutics A~2B~ adenosine receptor antagonists

9-Deazaxanthines {#Sec3}
================

9-Deazaxanthines (pyrrolo\[2,3-*d*\]pyrimidinones) were initially explored by Grahner et al. as antagonists for the A~1~ and A~2~ AdoRs (Fig. [6](#Fig6){ref-type="fig"}) \[[@CR30]\]. In most cases, the authors observed that the structure-activity relationships (SAR) of 9-deazaxanthines are parallel to those of xanthine derivatives and also noticed an increased selectivity over A~1~ AdoR. The authors concluded that the xanthines and 9-deazaxanthines bind in the same mode to the adenosine receptors, and thus, the similar SAR. Hayallah et al. have investigated the N-1 monosubstituted 9-deazaxanthines, because the corresponding xanthines generally exhibit high A~2B~ AdoR selectivity \[[@CR17]\]. The compound 6-phenyl-3-propyl-1*H*-pyrrolo\[3,2-*d*\]pyrimidine-2,4(3*H*,5*H*)-dione **26** has displayed good A~2B~ AdoR affinity, but it did not exhibit good selectivity over the A~1~ AdoR as expected. Vidal et al. have synthesized 8-phenyl-9-deazaxanthines that have a sulfonamide linker at the *para*-position of the phenyl group, and many compounds exhibited good A~2B~ AdoR affinity \[[@CR31]\]. For instance, **27** of the above series displayed 6 nM affinity for the A~2B~ AdoR and displayed good selectivity. In a recent publication, Carotti et al. presented several 9-deazaxanthines that have piperidine amides and piperazine amide substitution at the *para*-position of the 8-phenyl group \[[@CR32]\]. Representatives from these classes, compounds **28** and **29** (Fig. [6](#Fig6){ref-type="fig"}), respectively, displayed both high affinity and selectivity for the A~2B~ AdoR. CVT chemists have explored the 8-pyrazolyl-9-deazaxanthines as A~2B~ AdoR antagonists \[[@CR33]\]. The *m*-F benzyl derivative **30**, 6-(1-(3-fluorobenzyl)-1*H*-pyrazol-4-yl)-1,3-dipropyl-1*H*-pyrrolo\[3,2-*d*\]pyrimidine-2,4(3*H*,5*H*)-dione, has good A~2B~ AdoR affinity, but it did not offer good selectivity over other the AdoR subtypes. The corresponding *m*-CF~3~ benzyl derivative **31** displayed lower affinity for the A~2B~ receptor than **30**, but it exhibited good selectivity for the A~2B~ AdoR. Overall the 9-deazaxanthines afforded similar SAR to the parent xanthines with respect to A~2B~ AdoR affinity and, in most cases, higher selectivity. Fig. 6Deazaxanthines as A~2B~ antagonists

Non-xanthine analogues {#Sec4}
======================

Two series of compounds, 2-aminopyridines and 2-aminopyrimidines, were published as A~2B~ AdoR antagonists in patent applications from Almirall Prodesfarma (Fig. [7](#Fig7){ref-type="fig"}) \[[@CR34], [@CR35]\]. From these series of compounds, Vidal et al. recently published on the common core and substituents, namely, *N*-heteroaryl 4′-furyl-4,5′-bipyrimidin-2′-amines, as high affinity and selective A~2B~ AdoR antagonists \[[@CR36]\]. For example, the 2′-amino(3-pyridyl) derivative **32** (LAS38096) has a A~2B~ affinity of 17 nM and has very good selectivity. Similar analogues, 2′-amino(5-pyrimidinyl) derivative **33** and 2′-amino(6-oxo-1,6-dihydropyridin-3-yl) derivative **34**, displayed good A~2B~ affinity of 24 and 16 nM, respectively, and both compounds have very good A~2B~ AdoR selectivity as well. Compound **32** inhibited the NECA-induced cAMP levels in HEK-293 expressing human A~2B~ AdoR and CHO cells transfected with mouse A~2B~ AdoR with IC~50~s of 321 nM and 349 nM, respectively. Following oral dosing in rats (10 mg/kg), compound **32** displayed good systemic exposure with a C~max~ of 11 µM and an AUC of 16 µM/h. It also displayed good exposure following oral dosing in mouse and dogs. Based on its in vitro pharmacology and pharmacokinetic profile, **32** was moved into preclinical development. Fig. 7Almirall A~2B~ antagonists

Adenine derivatives have been explored as adenosine receptor antagonists by several research groups (Fig. [8](#Fig8){ref-type="fig"}) \[[@CR37], [@CR38]\]. Cristalli and coworkers reported a series of 2-substituted 9-alkyl derivatives as selective A~2B~ receptor antagonists (not shown) \[[@CR39]\]. Harada et al. at Eisai explored the 2-alkynyl-8-aryl-9-methyl adenine derivatives as A~2B~ AdoR antagonists \[[@CR40]\]. Of these derivatives, compound **35** with a 3-F phenyl substitution at the 8-position displayed good A~2B~ affinity, but no binding selectivity over other AdoR subtypes (Fig. [8](#Fig8){ref-type="fig"}). Substituting the 3-F phenyl of **35** with a 2-furyl group provided compound **36** with good A~2B~ affinity, but again with no selectivity. Further optimization of the 9-position of the adenine derivative **35** led to the 3-benzamide derivative **37** with excellent A~2B~ affinity \[[@CR41]\]. Compound **37** displayed good selectivity over the A~1~ AdoR subtype only. These analogues inhibited NECA-induced cAMP production in CHO K1 cells expressing the human A~2B~ AdoR demonstrating that these compounds are antagonists. Further optimization of the SAR may lead to selective A~2B~ antagonists in the adenine series. Fig. 8Purines and 7-deazapurines as A~2B~ antagonists

In recent publications, scientists at OSI Pharmaceuticals have shown that 2-phenyl-7-deazaadenines (pyrrolopyrimidines) display good A~2B~ AdoR affinity (Fig. [8](#Fig8){ref-type="fig"}) \[[@CR42]\]. A lead compound **38** in the pyrrolopyrimidine series demonstrated excellent A~2B~ AdoR affinity and promising selectivity. A tritium-labeled analogue **39** (\[^3^H\]OSIP-339391) of **38** was synthesized, which displayed a *K*~D~ value of 0.41 ± 0.06 nM for binding to human A~2B~ AdoR expressed in HEK-293 cells. This represents a selective and high affinity radioligand that can be a useful tool in further characterization of the pharmacology of the A~2B~ AdoR.

Pharmacology discussion {#Sec5}
=======================

Since the goal of obtaining a high affinity and selective A~2B~ antagonist has been achieved by several research groups, the agents obtained have been used to establish the anti-inflammatory properties in both in vitro cellular studies and in asthma models. CVT chemists have synthesized several A~2B~-selective antagonists including **15** (CVT-6694) and **10** (CVT-6883). Following stimulation with a nonselective agonist NECA, compound **15** attenuated the increased production of both interleukin (IL)-6 and monocyte chemotactic protein-1 (MCP-1) in bronchoalveolar lavage smooth muscle cells \[[@CR25]\]. These experiments suggest a novel mechanism whereby adenosine acts as a proinflammatory mediator in the bronchiole airways. Similarly, A~2B~ AdoR subtype is the predominant AdoR expressed in human lung fibroblasts (HLFs), which on activation by NECA increases the release of IL-6 in a concentration-dependent manner and induces the differentiation of fibroblast into myofibroblasts \[[@CR43]\]. Synergy exists between hypoxia and NECA activation of the A~2B~ AdoR in HLFs, thus resulting in a pronounced increase in the release of IL-6. The A~2B~ antagonist **15** completely abolished the augmented effect of NECA on the IL-6 release; however, it as expected did not affect the hypoxia-induced release of IL-6 \[[@CR44]\]. In a mouse asthma model (ragweed challenge), compound **10** (dose: 1 mg/kg IP, 14-day treatment) was as effective as montelukast in reducing AMP-induced airway reactivity \[[@CR48]\]. Compound **10** reduced significantly bleomycin (3.0 U/kg)-induced pulmonary fibrosis and inflammation in mice \[[@CR47]\]. Furthermore, **10** (dose: 1 mg/kg IP b.i.d.) relative to vehicle controls reduced lung fibrosis and levels of macrophage-derived mediators of lung remodeling \[IL-6, osteopontin (OPN), transforming growth factor (TGF)-β1, and matrix metalloproteases (MMPs)\] in adenosine deaminase-deficient (ADA -/-) mice \[[@CR47]\].

The selective A~2B~ AdoR antagonist, MRE-2029-F20 synthesized by Baraldi's group, shows the inhibition of cAMP levels in neutrophils, lymphocytes, and HMC1 cells that naturally express the A~2B~ AdoR that may play a role in inflammatory diseases \[[@CR45]\]. The selective A~2B~ AdoR antagonist **32** (LAS38096) synthesized by Almirall has been shown to inhibit the NECA-induced production of IL-6 in a dose-dependent manner in both human and mouse fibroblasts \[[@CR36]\]. This further confirms the anti-inflammatory properties of A~2B~ AdoR antagonists.

Conclusion {#Sec6}
==========

Compound **10** (CVT-6883), a potent selective, orally available, and potentially first in class A~2B~ AdoR antagonist, has been entered into clinical trials by CV Therapeutics \[[@CR46]\]. The data from two phase 1 clinical trials, a single ascending dose study in 24 healthy volunteers and a multiple ascending dose study in 30 volunteers, demonstrated that CVT-6883 was safe and well tolerated with no serious adverse events reported. Furthermore, the pharmacokinetic results indicated the suitability of CVT-6883 for once daily chronic dosing. The potential utility of CVT-6883 is in several disease areas including asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis \[[@CR47], [@CR48]\].

The discovery of three selective, high affinity A~2B~ AdoR antagonists (**10**, **20**, and **32**) should aid in determining the pharmacological role of the A~2B~ AdoR in various disease states in animal models and in clinical trials.
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